All Stories

  1. PET/CT und PET/MRT bei Tumoren des Kopf-Hals-Bereichs
  2. Evaluation der intratherapeutischen Dosimetrie bei der 177Lu-HA-DOTATATE Therapie neuroendokriner Tumoren mittels SPECT, Ganzkörperszintigraphie und Gammasonde
  3. Non-Hodgkin-Lymphome − PET in Diagnostik und Therapiesteuerung
  4. In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT
  5. Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas
  6. Entwicklung eines kompetenzbasierten Lernzielkatalogs Nuklearmedizin für das Studium der Humanmedizin in Deutschland
  7. Cutaneous Manifestation of Sarcoidosis in Lower-Back Tattoo With Increased Uptake of 18F-FDG
  8. Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment
  9. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma
  10. AIDS-Related Central Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-L-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells
  11. Effect of lifelong antibiotic treatment for aortic arch prosthesis infection
  12. Differentiated Thyroid Cancer—Treatment: State of the Art
  13. Nuklearmedizin in Deutschland
  14. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18 F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic
  15. Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension
  16. Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma
  17. Positronenemissionstomographie 2013 in Deutschland
  18. Ga-68-PSMA-PET/CT bei Prostatakarzinom
  19. PET/CT bei CUP-Syndromen
  20. FDG-PET/CT-Diagnostik in der Gastroenterologie
  21. PET/CT bei CUP-Syndromen
  22. Zukünftige Indikationen der PET/CT
  23. FDG-PET/CT in der Nachsorge von kolorektalen Karzinomen
  24. FDG-PET/CT bei Fieber ungeklärter Genese
  25. F-18-Natriumfluorid-PET/CT zur Darstellung koronarer Plaquerupturen
  26. Ga-68-PSMA-PET/CT bei Prostatakarzinom
  27. Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany
  28. Evaluation of transcranial sonographic findings and MIBG cardiac scintigraphy in the diagnosis of idiopathic Parkinson's disease
  29. Is reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson’s disease?
  30. Nuclear medicine training and practice in Germany
  31. Summary Report of the First International Workshop on PET/MR Imaging, March 19–23, 2012, Tübingen, Germany
  32. Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer
  33. Nuclear Medicine in Europe: Education
  34. F-18-FDG-PET Confined Radiotherapy of Locally Advanced NSCLC With Concomitant Chemotherapy: Results of the PET-PLAN Pilot Trial
  35. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
  36. Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson’s disease
  37. Simultaneous Occurrence of Typical Carcinoid and Non–Small-Cell Lung Cancer in the Same Lung Lobe
  38. Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer
  39. FP-CIT SPECT Does Not Predict the Progression of Motor Symptoms in Parkinson’s Disease
  40. Nuklearmedizin in Deutschland
  41. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer
  42. Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors
  43. Skelettdiagnostik mittels 18F-Natriumfluorid-PET und -PET/CT
  44. Brain Tumor Imaging Using p-[123I]Iodo-L-Phenylalanine and SPECT
  45. Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma
  46. Positronenemissionstomographie 2008 in Deutschland – Ergebnisse der Erhebung und Standortbestimmung
  47. Risk stratification of solitary pulmonary nodules by means of PET using 18F-fluorodeoxyglucose and SUV quantification
  48. Nonrigid Versus Rigid Registration of Thoracic 18F-FDG PET and CT in Patients with Lung Cancer: An Intraindividual Comparison of Different Breathing Maneuvers
  49. Kranielle und extrakranielle sympathische Lewykörperchen-Degeneration beim Morbus Parkinson entwickeln sich zueinander synchron
  50. FDG-PET–Based Radiotherapy Planning in Lung Cancer: Optimum Breathing Protocol and Patient Positioning—An Intraindividual Comparison
  51. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: A systematic review.
  52. 122. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson’s disease
  53. FDG-PET zur Lymphknoten-Diagnostik des Lungenkarzinoms: Welche SUV-Schwelle ist sinnvoll?
  54. FDG-PET-basierte Bestrahlungsplanung von nicht kleinzelligen Bronchialkarzinomen: Optimales Atemprotokoll und Patientenpositionierung – ein intraindividueller Vergleich
  55. FDG- based GTVs for radiotherapy planning in lung cancer: influence of coregistration on volume size
  56. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data
  57. PET Imaging With p-[I-124]iodo-l-phenylalanine as a New Tool for Diagnosis and Postoperative Control in Patients With Glioma
  58. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial
  59. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson's disease
  60. Para-[123I]iodo-L-phenylalanine in patients with pancreatic adenocarcinoma
  61. Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease
  62. Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease
  63. 18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense?
  64. Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-α-methyl-tyrosine for SPECT imaging of gliomas
  65. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease
  66. PET-Plan Studie NSCLC: erste Erkenntnisse aus der Homburger Pilotstudie
  67. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer
  68. Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease
  69. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer
  70. Validation of brain tumour imaging with p-[123I]iodo-l-phenylalanine and SPECT
  71. Diagnostik des Bronchialkarzinoms
  72. Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-d-glucose in human pancreatic carcinoma xenografts and in inflammation models
  73. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
  74. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
  75. Value of FDG PET in the management of NSCLC
  76. p -[ 123 I]iodo-l-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma
  77. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy
  78. Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma
  79. Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-L-phenylalanine for routine brain tumour imaging
  80. Aussagekraft der Positronen-Emissions-Tomographie mit F-18-Fluordesoxyglukose (FDG-PET) beim Bronchioloalveolarzellkarzinom (BAC)
  81. Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren1 - Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000 -
  82. Isolated Cavitary Pulmonary Nodule and Positron Emission Tomography (PET) with F18 Fluorodesoxyglucose (FDG)
  83. Comparison of Early Pulmonary Changes in 18FDG-PET and CT after Combined Radiochemotherapy for Advanced Non-Small-Cell Lung Cancer: A Study in 15 Patients
  84. Stellenwert der Positronen-Emissions-Tomographie mit 18-Fluor-Desoxyglukose (FDG-PET) in der Rezidivdiagnostik des Bronchialkarzinoms
  85. Influence of diabetes mellitus on regional cerebral glucose metabolism and regional cerebral blood flow
  86. 18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis
  87. Diagnostische Aussagekraft der Positronen-Emissions-Tomographie (PET) bei zerebralen Metastasen von Bronchialkarzinomen
  88. Long-Term Side Effects after High Dose Radioiodine Therapy in Thyroid Carcinoma Patients
  89. Influence of Right Ventricular Stimulation Site on Left Ventricular Function in Atrial Synchronous Pacing
  90. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose